Alternative MM antigens that are being explored as targets for CAR therapy are CD38, SLAMF7, and CD138; however, on-target off-tumor expression of these antigens on other hematopoietic or non-hematopoietic cells compromises their safety profile. This evidence concerns the gene SLAMF7 and Miyoshi myopathy.